Enzastaurin inhibits human WM cell growth in vivo. (A) Mean tumor volume in the mice treated with enzastaurin (80 mg/kg twice daily) (●) or with vehicle (dextrose 5% in water twice daily) (▵). Error bars indicate the variation of tumor size between mice in each group. (B) Kaplan-Meier survival curve. Enzastaurin increased survival in the treated group (solid line, n = 9) compared to the control group treated with vehicle only (dotted line, n = 6) (P = .022). (C) Tumor tissues from mice treated with control vehicle (n = 3, rows 1, 2, 3) or daily enzastaurin (n = 3, rows 4, 5, 6) were harvested, processed, and subjected to Western blotting using anti–p-Akt (ser473), anti–p-GSK3β, and anti–β-actin antibodies.